Agenus Inc.
$7.85
Market Cap
$354.52M
Shares Outstanding
45.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 4, 2000
Round Lot
100
Locale
US
Day Open
$7.48
Day High
$7.88
Day Low
$7.33
Volume
2.08M
VWAP
$7.70
Prev Close
$7.22
Transactions
--
Acc. Volume
--
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Agenus Inc. (AGEN) closed the 2026-09-18 session at $7.85, up 8.73% versus the previous close (+0.63). The stock opened at $7.48 and traded between $7.33 and $7.88 during that session. Session trading volume was 2.1M shares. The volume-weighted average price (VWAP) is $7.70.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Agenus Inc. has a market capitalization of $354.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. AGEN is listed on the XNAS exchange. The company employs approximately 81 people. Agenus Inc. is headquartered in LEXINGTON, MA. The recorded listing date is 2000-02-04.
On this page you can find market AGEN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.